The future challenges facing the development of new antimicrobial drugs

Nature Reviews Drug Discovery

Volumn 1, Issue 11, 2002, Pages 895-910

  Coates, Anthony ^a,b   Hu, Yanmin ^a,b   Bax, Richard ^c   Page, Clive ^d  

^a ST GEORGE'S UNIVERSITY OF LONDON   (United Kingdom)

^b BioTherapies Ltd   (United Kingdom)

^c Adamis Pharmaceuticals Corporation   (United States)

^d KING'S COLLEGE LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIINFECTIVE AGENT; CARBAPENEM; CEFALOTIN; CEFAPIRIN; CEFEPIME; CEFOTAXIME; CEFTAZIDIME; CEPHALOSPORIN; CETHROMYCIN; DAPTOMYCIN; ERTAPENEM; ERYTHROMYCIN; FROPENEM; GATIFLOXACIN; GEMIFLOXACIN; LINEZOLID; MOXIFLOXACIN; NALIDIXIC ACID; ORITAVANCIN; PENICILLIN G; QUINUPRISTIN; RAMOPLANIN; RIFAMPICIN; SULFAMETHOXAZOLE; TELITHROMYCIN; TETRACYCLINE; TIGECYCLINE; TOBRAMYCIN; TRIMETHOPRIM; UNINDEXED DRUG;

ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; BACTEREMIA; CLINICAL TRIAL; DRUG COST; DRUG EFFICACY; DRUG INFORMATION; DRUG SCREENING; DRUG TARGETING; DRUG TOLERANCE; HUMAN; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PRIORITY JOURNAL; REVIEW; ANIMAL; METHODOLOGY; MULTIDRUG RESISTANCE; PHARMACEUTICS; PHYSIOLOGY; SYNTHESIS;

ANIMALS; ANTI-BACTERIAL AGENTS; DRUG RESISTANCE, MULTIPLE, BACTERIAL; HUMANS; TECHNOLOGY, PHARMACEUTICAL;

EID: 0036834373     PISSN: 14741776     EISSN: None     Source Type: Journal    
DOI: 10.1038/nrd940     Document Type: Review

References (166)

1. Austrian, R. & Gold, J. Pneumococcal bacteraemia with a special reference to bacteremic Pneumococcal pneumonia. Ann. Intern. Med. 60, 759-776 (1964).
2. Dineen, P., Homan, W. P. & Grafe, W. R. Tuberculous peritonitis: 43 years experience in diagnosis and treatment. Ann. Surg. 184, 717-722 (1976).
3. Bax, R. P. et al. Antibiotic resistance - what can we do? Nature Med. 4, 545-546 (1998).
4. Bax, R. P. & Mullan, N. Response of the pharmaceutical industry to antimicrobial resistance. Balliere Clin. Infect. Dis. 5, 289-304 (1999).
5. Thornsberry, C. et al. Regional trends in antimicrobial resistance among clinical isolates of Streptococcus pneumoniae, Haemophilus influenzae and Moraxella catarrhalis in the United States: results from the TRUST Surveillance Program, 1999-2000. Chn. Infect. Dis. 34, S4-S16 (2002).
6. National Center for Infectious Diseases. Campaign to prevent antimicrobial resistance in healthcare settings. Centers for Disease Control and Prevention [online] (cited 30 Sep 2002) http://www.cdc.gov/drugresistance/healthcare/problem.htm (2002).
7. Demyan, W. F. et al. in Program and Abstracts of the 37th International Conference on Antimicrobial Agents and Chemotherapy (ICAAC) Toronto Abstract 724 (American Society for Microbiology, Toronto, 1997).
8. Bryskier, A. Novelties in the field of anti-infective compounds in 1999. Clin. Infect. Dis. 31, 1423-1466 (2000).
9. Saussier-Morange, V. & Leclercq, R. (eds) in Program and Abstracts of the 40th International Conference on Antimicrobial Agents and Chemotherapy (ICAAC) Toronto Abstract 149 (American Society for Microbiology, Toronto, 2000).
10. Sievert, D. M. et al. Staphyloccocus aureus resistant to vancomycin - United States 2002. Morbid. Mortal. Wkly Rep. 51, 565-567 (2002).
11. Bax, R., Mullan, N. & Verhoef, J. The millennium bugs - the need for and development of new antibacterials. Int. J. Antimicrob. Agents 16, 51-59 (2000).
12. Chopra, I., Hodgson, J., Metcalf, B. & Poste, G. New approaches to the control of infections caused by antibiotic-resistant bacteria. An industry perspective. JAMA 275, 401-403 (1996).
13. House of Lords Select Committee on Science and Technology. Resistance to Antibiotics 7th Report (Stationary Office Session, London, 1997-1998).
14. The Academy of Medical Sciences. Academic Medical Bacteriology in the 21st Century (The Academy of Medical Sciences, London, 2001).
15. Carbon, C. & Bax, R. P. Regulating the use of antibiotics in the community. BMJ 317, 663-665 (1998).
16. World Health Organization. Report and Proceedings of a WHO Meeting in Berlin, Germany, 13-17 October 1997 WHO EM CL 97.4 (2001).
17. US General Accounting Office, The Agricultural Use of Antibiotics and Its Implications for Human Health. US General Accounting Office, Report to the Honorable Tom Harkin, Ranking Minority Member, Committee on Agriculture, Nutrition, and Forestry US Senate Document Number RCED-99-74 (April 1999).
18. Scheckler, W. E. et al. Requirements for infrastructure and panel report. Infect. Control Hosp. Epidemiol. 19, 114-124 (1998).
19. Pallares, D. et al. Trends in antimicrobials utilization in a tertiary teaching hospital during a 15 year period (1978-1992). Infect. Control Hosp. Epidemiol. 14, 376-382 (1993).
20. Goldman, D. A. et al. Strategies to prevent and control the emergence and spread of antimicrobial resistant organisms in hospitals. A challenge to hospital leadership? JAMA 255, 234-240 (1996).
21. Peltola, H., Kilpi, T. & Anttila, M. Rapid disappearance of Haemophilus influenzae type b meningitis after routine childhood immunization with conjugate vaccines. Lancet 340, 592-594 (1992).
22. Centres for Disease Control and Prevention. Progress towards eliminating Haemophilus influenzae type b disease among infants and children. United States 1987-1997. Morbid. Mortal. Wkly Rep. 47, 993-998 (1998).
23. Subcommittee on Public Health. Antimicrobial Resistance: solutions for this growing public health threat. Senate Committee on Health, Education, Labor, and Pensions [online] (cited 30 Sep 2002) http://www.senate.gov/%7Elabor/hearings/febhear/febhear.htm (1999).
24. National Center for Infectious Diseases. Campaign to prevent antimicrobial resistance in healthcare settings. Centers for Disease Control and Prevention [online] (cited 30 Sep 2002) http://www.cdc.gov/drugresistance/healthcare/problem.htm (2002).
25. National Center for Infectious Diseases. Background on antibiotic resistance. Centers for Disease Control and Prevention [online] (cited 30 Sep 2002) http://www.cdc.gov/drugresistance/community (2002).
26. Bax, R., Gabbay, F. & Phillips, I. The Whitely Park study group, antibiotic clinical trials. Clin. Microbiol. Infect. 5, 774-787 (1999).
27. Baquero, F., Bax, R. & Phillips, I. Antibiotic clinical trials revisited. J. Antimicrob. Chemother. 45, 651-652 (2000).
28. Schlaes, D., Levy, S. & Archer, G. Antimicrobial resistance - new directions. ASM News 57, 455-458 (1991).
29. Daly, J. S., Eliopoulos, G. M., Willey, S. & Moellering, R. C. Jr. Mechanism of action and in vitro and in vivo activities of S-6123, a new oxazolidinone compound. Antimicrob. Agents Chemother. 32, 1341-1346 (1988).
30. Tsiodras, S. et al. Linezolid resistance in a clinical isolate of Staphylococcus aureus. Lancet 358, 207-208 (2001).
31. Gonzales, R. D. et al. Infections due to vancomycin-resistant Enterococcus faecium resistant to linezolid. Lancet 357, 1179 (2001).
32. Mandell, G. L., Bennett, J. & Dolin, R. (ads) in Principles and Practice of infectious Diseases 5th edn 261-448 (Churchill Livingstone, Philadelphia, (2000).
33. Walsh, C. Molecular mechanisms that confer antibacterial drug resistance. Nature 406, 775-781 (2000).
34. Spratt, B. G. Biochemical and genetic approaches to the mechanism of action of penicillin. Phil. Trans. R. Soc. Lond. B 289, 273-283 (1980).
35. Smith, J. T. The mode of action of 4-quinolones and possible mechanisms of resistance. J. Antimicrob. Chemother. 18, 21-29 (1984).
36. Wehrli, W. et al. Interaction of rifamycin with bacterial RNA polymerase. Proc. Natl Acad. Sci. USA 61, 667-673 (1968).
37. Goldman, R. C., Fesik, S. W. & Doran, C. Role of protonated and neutral forms of macrolides in binding to ribosomes from Gram-positive and Gram-negative bacteria. Antimicrob. Agents Chemother. 34, 426-431 (1990).
38. Hitchings, G. T. in Trimethoprim/Sulphamethozale in Bacterial Infections (eds Bernstein, L. & Salter, A.) 7-16 (Churchill Livingstone, Edinburgh and London, 1973).
39. Woods, D. D. Relation of p-aminobenzoic acid to mechanism of action of sulphanilamide. Br. J. Exp. Pathol. 21, 74-90 (1940).
40. Fleming, A. On the antibacterial action of cultures of a penicillium, with special reference to their use in the isolation of B. influenzae. Br. J. Exp. Pathol. 10, 226-236 (1929).
41. Gardner, P. et al. Recovery of resistance factors from a drug-free community. Lancet 2, 774-776 (1969).
42. Opal, S. M., Mayer, K. & Medeiros, A. in Mechanisms of Bacterial Antibiotic Resistance. Principles and Practice of Infectious Diseases 5th edn Ch. 16 (eds. Mandell, G. L., Bennett, J. & Dolin, R.) 236-253 (Churchill Livingstone, Philadelphia, 2000).
43. Sefton, A. M. Mechanisms of antimicrobial resistance: their clinical relevance in the new millennium. Drugs 62, 557-566 (2002).
44. Medeiros, A. A. Evolution and dissemination of β-lactamases accelerated by generations of β-lactam antibiotics. Clin. Infect. Dis. 24, S19-S45 (1997).
45. Amsden, G., Ballow, C. & Bertino, J. Pharmacokinetics and Pharmacodynamics of Anti-Infective Agents. Principles and Practice of infectious Diseases Ch. 17 (eds Mandell G. L., Bennett, J. & Dolin, R.) 253-260 (Church Livingstone, Philadelphia, 2000).
46. Spratt, B. G. Resistance to antibiotics mediated by target alterations. Science 264, 388-393 (1994).
47. Cunha, B. A. Strategies to control antibiotic resistance. Semin. Respir. Infect. 17, 250-258 (2002).
48. Farra, A. et al. Antibiotic use and Escherichia coli resistance trends for quinolones and cotrimoxazole in Sweden. Scand. J. Infect. Dis. 34, 449-455 (2002).
49. Gold, H. S., Moellering, R. C. Jr. Antimicrobial drug resistance. N. Engl. J. Med. 335, 1445-1453 (1996).
50. Sykes, R. B. & Matthew, M. The β-lactamases of Gram-negative bacteria and their resistance to β-lactam antibiotics. J. Antimicrob. Chemother. 2, 115-157 (1976).
51. Jacoby, G. A. & Medeiros A. A. More extended-spectrum β-lactamases. Antimicrob. Agents Chemother. 35, 1697-1704 (1994).
52. Amyes, S. G. & Smith, J. T. R-factor mediated dihydrofolate reductases which confer trimethoprim resistance. J. Gen. Microbiol. 107, 263-271 (1978).
53. Livermore, D, M. Interplay of impermeability and chromosomal β-lactamase activity in impenem resistant Pseudomonas aeruginosa. Antimicrob. Agents Chemother. 36, 2046-2048 (1992).
54. Williams, J. B. Drug efflux as a mechanism of resistance. Br. J. Biomed. Sci. 53, 290-293 (1996).
55. Spoering, A. L. & Lewis, K, Biofilms and planktonic cells of Pseudomonas aeruginosa have similar resistance to killing by antimicrobials. J. Bacteriol. 183, 6746-6751 (2001).
56. Groicher, K. H., Firek, B. A., Fujimoto, D. F. & Bayles, K. W. The Staphylococcus aureus IrgAB operon modulates murein hydrolase activity and penicillin tolerance. J. Bacteriol. 182, 1794-1801 (2000).
57. Van Asselt, G. J. & Mouton, R. P. Detection of penicillin tolerance in Streptococcus pyagenes. J. Med. Microbiol. 38, 197-202 (1993).
58. Davey, P., Barza, M. & Stuart, M. Tolerance of Pseudomonas aeruginosa to killing by ciprofloxacin, gentamicin and imipenem in vitro and in vivo. J. Antimicrob. Chemother. 4, 395-404 (1988).
59. Hu, Y. & Coates, A. R. Increased levels of sigJ mRNA in late stationary phase cultures of Mycobacterium tuberculosis detected by DNA array hybridisation. FEMS Microbiol. Lett. 202, 59-65 (2001).
60. Hu, Y. et al. Detection of mRNA transcripts and active transcription in persistent Mycobacterium tuberculosis induced by exposure to rifampin or pyrazinamide. J. Bacteriol. 182, 6358-6365 (2000).
61. Bangham, C. et al. in Evolution in Health and Disease (ed. Stearns, S. C.) 152-160 (Oxford Univ. Press, 1999).
62. Watve, M. G., Tickoo, R., Jog, M. M. & Bhole, B. D. How many antibiotics are produced by the genus Streptomyces? Arch. Microbiol. 176, 386-390 (2001).
63. Silver, L. & Bastian, K. Screening of natural products for antimicrobial agents. Eur. J. Clin. Microbiol. Infect. Dis. 9, 455-461 (1990).
64. Nizet, V. et al. Innate antimicrobial peptide protects the skin from invasive bacterial infection. Nature 414, 454-457 (2001).
65. MacNeil, I. A. et al. Expression and isolation of antimicrobial small molecules from soil DNA libraries. J. Mol. Microbiol. Biotechnol. 3, 301-308 (2001).
66. Knowles, D. J. New strategies for antibacterial drug design. Trends Microbiol. 5, 379-383 (1997).
67. Gootz, T. D. Discovery and development of new antimicrobial agents. Clin. Microbiol. Rev. 3, 13-31 (1990).
68. O'Callaghan C. H. et al. Cefuroxime, a new cephalosporin antibiotic: activity in vitro. Antimicrob. Agents Chemother. 13, 657-664 (1978).
69. Neu, H. C. Structure-activity relations of new β-lactam compounds and in vitro activity against common bacteria. Rev. Infect. Dis. 5, S319-S337 (1983).
70. Allan, J. D., Eliopoulos, G. M. & Moellering, R. C. Jr. in Contempory Issues in Infectious Diseases Vol. 6 (eds Root, R. K., Trunkey, D. D. & Sande, M. A.) 263-284 (Churchill Livingstone, New York, 1987).
71. Hopwood, D.A. et al. Production of 'hybrid' antibiotics by genetic engineering. Nature 314, 642-644 (1985).
72. Omura, S., Ikeda, H., Malpartida, F., Kieser, H. M. & Hopwood, D. A. Production of new hybrid antibiotics, mederrhodins A and B, by a genetically engineered strain. Antimicrob. Agents Chemother. 29, 13-19 (1986).
73. Pfeifer, B. A., Admiraal, S. J., Gramajo, H., Cane, D. E. & Khosla, C. Biosynthesis of complex polyketides in a metabolically engineered strain of E. coli. Science 291, 1790-1792 (2001).
74. Bentley, R. & Bennett, J. W. Constructing polyketides: from collie to combinatorial biosynthesis. Annu. Rev. Microbiol. 53, 411-446 (1999).
75. Cane, D. E., Walsh, C. T. & Khosla, C. Harnessing the biosynthetic code: combinations, permutations, and mutations. Science 282, 63-68 (1998).
76. Hopwood, D. A. Genetic engineering of Streptomyces to create hybrid antibiotics. Curr. Opin. Biotechnol. 4, 531-537 (1993).
77. Kohli, R. M., Walsh, C. T. & Burkart, M. D. Biomimetic synthesis and optimization of cyclic peptide antibiotics. Nature 418, 658-661 (2002).
78. The Wellcome Trust Sanger Institute. Microbial genomes. The Wellcome Trust Sanger Institute [online] (cited 30 Sep 2002) http://www.sanger.ac.uk/Projects/Microbes/ (2002).
79. Tettelin, F. et al. Finding drug targets in microbial genomes. Drug Discov. Today 6, 887-892 (2001).
80. Allsop, A. E. (1998). New antibiotic discovery, novel screens, novel targets and impact of microbial genomics. Curr. Opin. Microbiol. 1, 530-534 (1998).
81. Rosamund, J. & Allsop. A. Harnessing the power of the genome in the search for new antibiotics. Science 287, 1973-1976 (2000).
82. Black, T. & Hare, R. Will genomics revolutionize antimicrobial drug discovery? Curr. Opin. Microbiol. 3, 522-527 (2000).
83. Payne, D. J. et al. The impact of genomics on novel antibacterial targets. Curr. Opin. Drug Discov. Dev. 3, 177-190 (2000).
84. Payne, D. J. et al. Delivering novel targets and antibiotics from genomics. Curr. Opin. Invest. Drugs 2, 1028-1034 (2001).
85. McDevitt, D. et al. (2002). Novel targets for the future development of antibacterial agents. Symp. Ser. Soc. Appl. Microbiol. 92, 28S-34S
86. Chopra, I. et al. Exploiting current understanding of antibiotic action for discovery of new drugs. Symp. Ser. Soc. Appl. Microbiol. 92, 4S-15S (2002).
87. Rosenberg, M. & McDevitt, D. Exploiting genomics to discover new antibiotics. Trends Microbiol. 9, 611-617 (2001).
88. Connelly, G. P. Substrate profiling of new enzymes for drug discovery. Fed. Res. Progress NDN-049-0330-1033-1 (2001).
89. Lazazzera, B. A. Quorum sensing and starvation: signals for entry into stationary phase. Curr. Opin. Microbiol. 3, 177-182 (2000).
90. Mardis, E., McPherson, J., Martienssen, R., Wilson, R. K. & McCombie, W. R. What is finished, and why does it matter. Genome Res. 12, 669-671 (2002).
91. Potera, C. Microbial genomics grows in maturity and status. ASM News 68, 271-276 (2002).
92. Good, L., Awasthi, S. K., Dryselius, R., Larsson, O. & Nielsen, P. E. Bactericidal antisense effects of peptide-PNA conjugates. Nature Biotechnol. 19, 360-364 (2001).
93. Green, D. W. The bacterial cell wall as a source of antibacterial targets. Expert Opin. Ther. Targets 6, 1-19 (2002).
94. Coates, A. R. M. (ed.) Dormancy and Low Growth States in Microbial Diseases (Cambridge Univ. Press; in the press)
95. Driks, A. Maximum shields: the assembly and function of the bacterial spore coat. Trends Microbiol. 10, 251-254 (2002).
96. Takamatsu, H. & Watabe, K. Assembly and genetics of spore protective structures. Cell. Mol. Life Sci. 59, 434-444 (2002).
97. Mukamolova G. V., Kaprelyants, A. S., Young, D. I., Young, M. & Kell, D. B. A bacterial cytokine. Proc. Natl Acad. Sci. USA 95, 8916-8921 (1998).
98. Mukamolova, G. V., Kormer, S. S., Kell, D. B. & Kaprelyants, A. S. Stimulation of the multiplication of Micrococcus luteus by an autocrine growth factor. Arch. Microbiol. 172, 9-14 (1999).
99. Thom, S. M., Horobin, R. W., Seidler, E. & Barer, M. R. Factors affecting the selection and use of tetrazolium salts as cytochemical indicators of microbial viability and activity. J. Appl. Bacteriol. 74, 433-443 (1993).
100. Phillips, Z. E. & Strauch, M. A. Bacillus subtilis sporulation and stationary phase gene expression. Cell. Mol. Life Sci. 59, 392-402 (2002).
101. Rozen, Y. & Belkin, S. Survival of enteric bacteria in seawater. FEMS Microbiol. Rev. 25, 513-529 (2001).
102. Nystrom, T. Not quite dead enough: on bacterial life, culturability, senescence and death. Arch. Microbiol. 176, 159-164 (2001).
103. Spector, M. P. The starvation-stress response (SSR) of Salmonella. Adv. Microb. Physiol. 40, 233-279 (1998).
104. Hengge-Aronis, R. Back to log phase: sigma S as a global regulator in the osmotic control of gene expression in Escherichia coli. Mol. Microbiol. 21, 887-893 (1996).
105. Barer, M. R. in Dormancy and Low Growth States in Microbial Diseases (ed. Coates, A. R. M.) (Cambridge Univ. Press; in the press).
106. Spoering, A. L. & Lewis, K. Biofilms and planktonic cells of Pseudomonas aeruginosa have similar resistance to killing by antimicrobials. J. Bacteriol. 183, 6746-6751 (2001).
107. Lewis, K. Riddle of biofilm resistance. Antimicrob. Agents Chemother. 45, 999-1007 (2001).
108. Mitchison, D. A. Role of individual drugs in the chemotherapy of tuberculosis. Int. J. Tuberc. Lung Dis. 4, 796-806 (2000).
109. Herbert, D. et al. Bactericidal action of ofloxacin, sulbactam-ampicillin, rifampin, and isoniazid on logarithmic and stationary-phase cultures of Mycobacterium tuberculosis. Antimicrob. Agents Chemother. 40, 2296-2299 (1996).
110. Ashby, M. J., Neale, J. E., Knott, S. J. & Critchley, I. A. Effect of antibiotics on non-growing planktonic cells and biofilms of Escherichia coli. J. Antimicrob. Chemother. 33, 443-452 (1994).
111. McCune, R. M., Feldmann, F. M., Lambert, H. P. & McDermott, W. Microbial persistence. I. The capacity of tubercle bacilli to survive sterilization in mouse tissues. J. Exp. Med. 123, 445-468 (1966).
112. Mitchison, D. A. How drug resistance emerges as a result of poor compliance during short course chemotherapy for tuberculosis. Int. J. Tuberc. Lung Dis. 2, 10-15 (1998).
113. Szeto, C. C. et al. Clinical course of peritonitis due to Pseudomonas species complicating peritoneal dialysis: a review of 104 cases. Kidney Int. 59, 2309-2315 (2001).
114. Lutters, M. & Vogt, N. Antibiotic duration for treating uncomplicated, symptomatic lower urinary tractinfections in elderly women (Cochrane Review). Cochrane Database Syst Rev. CD001535 (2002).
115. Tuomanen, E. & Tomasz, A. Induction of autolysis in nongrowing Escherichia coli. J. Bacteriol. 167, 1077-1080 (1986).
116. Tuomanen, E. & Tomasz, A. Mechanism of phenotypic tolerance of nongrowing pneumococci to β-lactam antibiotics. Scand. J. Infect. Dis. Suppl. 74, 102-112 (1990).
117. Walson, J. L., Marshall, B., Pokhrel, B. M., Kafle, K. K. & Levy, S. B. Carriage of antibiotic-resistant fecal bacteria in Nepal reflects proximity to Kathmandu. J. Infect. Dis. 184, 1163-1169 (2001).
118. Millar, M. R. et al. Carriage of antibiotic-resistant bacteria by healthy children. J. Antimicrob. Chemother. 47, 605-610 (2001).
119. van de Mortel, H. J. et al. The prevalence of antibiotic-resistant faecal Escherichia coli in healthy volunteers in Venezuela. Infection 26, 292-297 (1998).
120. Shanahan, P. M., Thomson, C. J. & Amyes, S. G. β-Lactam resistance in normal faecal flora from South Africa. Epidemiol. Infect. 115, 243-253 (1995).
121. Bonten, M., Stobberingh, E., Philips, J. & Houben, A. Antibiotic resistance of Escherichia coli in fecal samples of healthy people in two different areas in an industrialized country. Infection 20, 258-262 (1992).
122. Lidin-Janson, G., Falsen, E., Jodal, U., Kaijser, B. & Lincoln, K. Characteristics of antibiotic-resistant Escherichia coli in the rectum of healthy school children. J. Med. Microbiol. 10, 299-308 (1977).
123. Cazzola, M., Matera, M. G. & Noschese, P. Parenteral antibiotic therapy in the treatment of lower respiratory tract infections. Strategies to minimize the development of antibiotic resistance. Pulm. Pharmacol. Ther. 13, 249-256 (2000).
124. Lambert, H. P. Don't keep taking the tablets? Lancet 354, 943-945 (1999).
125. Zhao, X. & Drlica, K. Restricting the selection of antibiotic-resistant mutant bacteria: measurement and potential use of the mutant selection window. J. Infect. Dis. 185, 561-565 (2002).
126. Martinez, J. L. & Baquero, F. Mutation frequencies and antibiotic resistance. Antimicrob. Agents Chemother. 44, 1771-1777 (2000).
127. Taddei, F., Matic, I. & Radman, M. cAMP-dependent SOS induction and mutagenesis in resting bacterial populations. Proc. Natl Acad. Sci. USA 92, 11736-11740 (1995).
128. Hughes, D. & Andersson, D. I. Carbon starvation of Salmonella typhimurium does not cause a general increase of mutation rates. J. Bacteriol. 179, 6688-6691 (1997).
129. Riesenfeld, C., Everett, M., Piddock, L. J. & Hall, B. G. Adaptive mutations produce resistance to ciprofloxacin. Antimicrob. Agents Chemother. 41, 2059-2060 (1997).
130. Alonso, A., Campanario, E. & Martinez, J. L. Emergence of multidrug-resistant mutants is increased under antibiotic selective pressure in Pseudomonas aeruginosa. Microbiology 145, 2857-2862 (1999).
131. Wermeille, J. et al. Failure of Helicobacter pylori eradication: is poor compliance the main cause? Gastroenterol. Clin. Biol. 26, 216-219 (2002).
132. Leclercq, R. Safeguarding future antimicrobial options: strategies to minimize resistance. Clin. Microbiol. Infect. 7, 18-23 (2001).
133. Pradier, C., Dunais, B., Carsenti-Etesse, H. & Dellamonica, P. Pneumococcal resistance patterns in Europe. Eur. J. Clin. Microbiol. Infect. Dis. 16, 644-647 (1997).
134. Wilkinson, D. Eight years of tuberculosis research in Hlabisa - what have we learned? S. Afr. Med. J. 89, 155-159 (1999).
135. Ball, P. et al. Antibiotic therapy of community respiratory tract infections: strategies for optimal outcomes and minimized resistance emergence. J. Antimicrob. Chemother. 49, 31-40 (2002).
136. Adam, D. Short-course antibiotic therapy for infections with a single causative pathogen. J. Int. Med. Res. 28, 13A-24A (2000).
137. Andes, D. & Craig, W. Animal model pharmacokinetics and pharmacodynamics: a critical review. Int. J. Antimicrob. Agents 19, 261-268 (2002).
138. Craig, W. Pharmacokinetic/pharmacodynamic parameters, rationale for antibacterial dosing of mice and men. Clin. Infect. Dis. 26, 1-10 (1998).
139. Forest, A. Pharmacodynamics of intravenous ciprofloxacin in seriously ill patients. Antimicrob. Agents Chemother. 37, 1073-1081 (1993).
140. Grange, J. M. Mycobacteria and Human Disease (Edward Arnold, London, 1988).
141. Eliopoulos, G. M. & Moellering, R. C. Jr. Antibiotic synergism and antimicrobial combinations in clinical infections. Rev. Infect. Dis. 4, 282-293 (1982).
142. Lynch, J. P. Hospital-acquired pneumonia: risk factors, microbiology, and treatment. Chest 119, 373S-384S (2001).
143. Banerjee, D. & Stableforth, D. The treatment of respiratory pseudomonas infection in cystic fibrosis: what drug and which way? Drugs 60, 1053-1064 (2000).
144. Graham, D. Y. et al. Metronidazole containing quadruple therapy for infection with metronidazole resistant Helicobacter pylori: a prospective study. Aliment Pharmacol. Ther. 14, 745-750 (2000).
145. Mebis, J. et al. Decreasing antibiotic resistance of enterobacteriaceae by introducing a new antibiotic combination therapy for neutropenic fever patients. Leukemia 12, 1627-1629 (1998).
146. Mouton, J. W. Combination therapy as a tool to prevent emergence of bacterial resistance. Infection 27, S24-S28 (1999).
147. Howe, R. A., Spencer, R. C. Cotrimoxazole. Rationale for re-examining its indications for use. Drug Saf. 14, 213-218 (1996).
148. Gupta, K. Addressing antibiotic resistance. Am. J. Med. 113, 29S-34S (2000).
149. Mereghetti, L., Marquet-van der Mee, N., Loulergue, J., Rolland, J. C. & Audurier, A. Pseudomonas aeruginosa from cystic fibrosis patients: study using whole cell RAPD and antibiotic susceptibility. Pathol. Biol. (Paris) 46, 319-324 (1998).
150. Mitchison, D. A. Basic mechanisms of chemotherapy. Chest 76, 771-781 (1979).
151. Mitchison, D. A. Mechanisms of tuberculosis chemotherapy. J. Pharm. Parmacol. 49, 31-36 (1997).
152. Rand, J. D., Danby, S. G., Greenway, D. L. & England, R. R. Increased expression of the multidrug efflux genes acrAB occurs during slow growth of Escherichia coli. FEMS Microbiol Lett. 207, 91-95 (2002).
153. Williams, M. D., Ouyang, T. X. & Flickinger, M. C. Starvation-induced expression of SspA and SspB: the effects of a null mutation in sspA on Escherichia coli protein synthesis and survival during growth and prolonged starvation. Mol. Microbiol. 11, 1029-1043 (1994).
154. Gustavsson, N., Diez, A. & Nystrom, T. The universal stress protein paralogues of Escherichia coli are co-ordinately regulated and co-operate in the defence against DNA damage. Mol. Microbiol. 43, 107-117 (2002).
155. Selinger, D. W. et al. RNA expression analysis using a 30 base pair resolution Escherichia coli genome array. Nature Biotechnol. 18, 1262-1268 (2000).
156. Wayne, L. G. & Sohaskey, C. D. Nonreplicating persistence of Mycobacterium tuberculosis. Annu. Rev. Microbiol. 55, 139-163 (2001).
157. Sudre, P., ten Dam, G. & Kochi, A. Tuberculosis: a global overview of the situation today. Bull. World Health Org. 70, 149-159 (1992).
158. Perez-Stable, E. J. & Hopewell, P. C. Current tuberculosis treatment regimens. Clin. Chest Med. 10, 323-339 (1989).
159. Kremer, L. S. & Besra, G. S. Current status and future development of antitubercular chemotherapy. Expert Opin. Investig. Drugs 11, 1033-1049 (2002).
160. Craig, W. A. & Ebert, S. C. Killing and regrowth of bacteria in vitro: A review. Scand. J. Infect. Dis. 74, 63-70 (1991).
161. Lewis, K. Programmed death in bacteria. Microbiol. Mol. Biol. Rev. 64, 503-514 (2000).
162. Moyed, H. S. & Bertrand, K. P. hipA, a newly recognized gene of Escherichia coli K-12 that affects frequency of persistence after inhibition of murein synthesis. J. Bacteriol. 155, 768-775 (1983).
163. Novak, R., Henriques, B., Charpentier, E., Normark, S. & Tuomanen, E. Emergence of vancomycin tolerance in Streptococcus pneumoniae. Nature 399, 590-593 (1999).
164. Piddock, L. J. & Walters, R. N. Bactericidal activities of five quinolones for Escherichia coli strains with mutations in genes encoding the SOS response or cell division. Antimicrob. Agents Chemother. 36, 819-825 (1992).
165. Rodionov, D. G. & Ishiguro, E. E. Direct correlation between overproduction of guanosine 3′,5′-bispyrophosphate (ppGpp) and penicillin tolerance in Escherichia coli. J. Bacteriol. 177, 4224-4229 (1995).
166. Kucers, A. & Bennett, N. M. The Use of Antibiotics: Comprehensive Review 4th edn (Lippincott, Philadelphia, 1989).